← FDA DRUG APPROVALS

FDA ANDA · ANDA062755

NALLPEN

Sponsor: GLAXOSMITHKLINE

APPLICATION
ANDA062755
TYPE
ANDA
ORIGINAL APPROVAL
1986-12-19
LATEST ACTION
1993-06-29
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

NALLPENDiscontinued
NAFCILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
NALLPENDiscontinued
NAFCILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

1993-06-29Labeling · Supplement 6AP
1986-12-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →